Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
DSCI's Cash to Debt is ranked higher than
92% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.41 vs. DSCI: No Debt )
Ranked among companies with meaningful Cash to Debt only.
DSCI' s 10-Year Cash to Debt Range
Min: 0.01  Med: 0.57 Max: No Debt
Current: No Debt
Equity to Asset 0.90
DSCI's Equity to Asset is ranked higher than
93% of the 169 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. DSCI: 0.90 )
Ranked among companies with meaningful Equity to Asset only.
DSCI' s 10-Year Equity to Asset Range
Min: 0.28  Med: 0.67 Max: 0.94
Current: 0.9
0.28
0.94
Interest Coverage No Debt
DSCI's Interest Coverage is ranked higher than
89% of the 104 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 38.48 vs. DSCI: No Debt )
Ranked among companies with meaningful Interest Coverage only.
DSCI' s 10-Year Interest Coverage Range
Min: 0.23  Med: 2.76 Max: 9999.99
Current: No Debt
0.23
9999.99
F-Score: 4
Z-Score: 7.55
M-Score: -3.16
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -47.95
DSCI's Operating margin (%) is ranked lower than
85% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.07 vs. DSCI: -47.95 )
Ranked among companies with meaningful Operating margin (%) only.
DSCI' s 10-Year Operating margin (%) Range
Min: -47.89  Med: -4.80 Max: 4.71
Current: -47.95
-47.89
4.71
Net-margin (%) -48.06
DSCI's Net-margin (%) is ranked lower than
85% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.54 vs. DSCI: -48.06 )
Ranked among companies with meaningful Net-margin (%) only.
DSCI' s 10-Year Net-margin (%) Range
Min: -47.49  Med: -7.41 Max: 2.4
Current: -48.06
-47.49
2.4
ROE (%) -29.75
DSCI's ROE (%) is ranked lower than
82% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.64 vs. DSCI: -29.75 )
Ranked among companies with meaningful ROE (%) only.
DSCI' s 10-Year ROE (%) Range
Min: -71.88  Med: -16.70 Max: 6.13
Current: -29.75
-71.88
6.13
ROA (%) -27.29
DSCI's ROA (%) is ranked lower than
85% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.56 vs. DSCI: -27.29 )
Ranked among companies with meaningful ROA (%) only.
DSCI' s 10-Year ROA (%) Range
Min: -41.07  Med: -10.99 Max: 4.65
Current: -27.29
-41.07
4.65
ROC (Joel Greenblatt) (%) -194.82
DSCI's ROC (Joel Greenblatt) (%) is ranked lower than
89% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.56 vs. DSCI: -194.82 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DSCI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -207.97  Med: -23.28 Max: 18.19
Current: -194.82
-207.97
18.19
Revenue Growth (3Y)(%) -21.80
DSCI's Revenue Growth (3Y)(%) is ranked lower than
91% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. DSCI: -21.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
DSCI' s 10-Year Revenue Growth (3Y)(%) Range
Min: -40.2  Med: -11.80 Max: 11.5
Current: -21.8
-40.2
11.5
EBITDA Growth (3Y)(%) 119.00
DSCI's EBITDA Growth (3Y)(%) is ranked higher than
98% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.70 vs. DSCI: 119.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
DSCI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -75.4  Med: 0.10 Max: 161.3
Current: 119
-75.4
161.3
EPS Growth (3Y)(%) 49.00
DSCI's EPS Growth (3Y)(%) is ranked higher than
91% of the 125 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. DSCI: 49.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
DSCI' s 10-Year EPS Growth (3Y)(%) Range
Min: -29.7  Med: 3.00 Max: 122.4
Current: 49
-29.7
122.4
» DSCI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

DSCI Guru Trades in Q2 2014

Chuck Royce 55,000 sh (unchged)
Jim Simons Sold Out
» More
Q3 2014

DSCI Guru Trades in Q3 2014

Chuck Royce 55,000 sh (unchged)
» More
Q4 2014

DSCI Guru Trades in Q4 2014

Jim Simons 15,623 sh (New)
Chuck Royce 162,100 sh (+194.73%)
» More
Q1 2015

DSCI Guru Trades in Q1 2015

Jim Simons 141,608 sh (+806.41%)
Chuck Royce 342,600 sh (+111.35%)
» More
» Details

Insider Trades

Latest Guru Trades with DSCI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.51
DSCI's P/B is ranked higher than
75% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.86 vs. DSCI: 1.51 )
Ranked among companies with meaningful P/B only.
DSCI' s 10-Year P/B Range
Min: 0.5  Med: 1.43 Max: 3.42
Current: 1.51
0.5
3.42
P/S 2.13
DSCI's P/S is ranked higher than
60% of the 186 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.69 vs. DSCI: 2.13 )
Ranked among companies with meaningful P/S only.
DSCI' s 10-Year P/S Range
Min: 0.21  Med: 0.67 Max: 3.26
Current: 2.13
0.21
3.26
Current Ratio 8.53
DSCI's Current Ratio is ranked higher than
93% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.55 vs. DSCI: 8.53 )
Ranked among companies with meaningful Current Ratio only.
DSCI' s 10-Year Current Ratio Range
Min: 1.05  Med: 2.11 Max: 15.92
Current: 8.53
1.05
15.92
Quick Ratio 7.08
DSCI's Quick Ratio is ranked higher than
94% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.68 vs. DSCI: 7.08 )
Ranked among companies with meaningful Quick Ratio only.
DSCI' s 10-Year Quick Ratio Range
Min: 0.4  Med: 1.28 Max: 13.56
Current: 7.08
0.4
13.56
Days Inventory 110.54
DSCI's Days Inventory is ranked higher than
62% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 128.70 vs. DSCI: 110.54 )
Ranked among companies with meaningful Days Inventory only.
DSCI' s 10-Year Days Inventory Range
Min: 85.54  Med: 111.51 Max: 346.75
Current: 110.54
85.54
346.75
Days Sales Outstanding 35.91
DSCI's Days Sales Outstanding is ranked higher than
88% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.15 vs. DSCI: 35.91 )
Ranked among companies with meaningful Days Sales Outstanding only.
DSCI' s 10-Year Days Sales Outstanding Range
Min: 14.87  Med: 38.69 Max: 119.02
Current: 35.91
14.87
119.02

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.37
DSCI's Price/Net Cash is ranked higher than
84% of the 44 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 12.20 vs. DSCI: 3.37 )
Ranked among companies with meaningful Price/Net Cash only.
DSCI' s 10-Year Price/Net Cash Range
Min: 0.4  Med: 5.54 Max: 272
Current: 3.37
0.4
272
Price/Net Current Asset Value 2.24
DSCI's Price/Net Current Asset Value is ranked higher than
90% of the 109 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.67 vs. DSCI: 2.24 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
DSCI' s 10-Year Price/Net Current Asset Value Range
Min: 0.19  Med: 2.68 Max: 9.91
Current: 2.24
0.19
9.91
Price/Tangible Book 1.94
DSCI's Price/Tangible Book is ranked higher than
71% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.27 vs. DSCI: 1.94 )
Ranked among companies with meaningful Price/Tangible Book only.
DSCI' s 10-Year Price/Tangible Book Range
Min: 0.17  Med: 1.62 Max: 9.9
Current: 1.94
0.17
9.9
Price/Median PS Value 3.18
DSCI's Price/Median PS Value is ranked lower than
96% of the 163 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.24 vs. DSCI: 3.18 )
Ranked among companies with meaningful Price/Median PS Value only.
DSCI' s 10-Year Price/Median PS Value Range
Min: 0.08  Med: 0.77 Max: 4.28
Current: 3.18
0.08
4.28
Earnings Yield (Greenblatt) (%) -35.31
DSCI's Earnings Yield (Greenblatt) (%) is ranked lower than
95% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.80 vs. DSCI: -35.31 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DSCI' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -36.09  Med: 29.60 Max: 48.5
Current: -35.31
-36.09
48.5

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Derma Sciences Inc was incorporated on September 10, 1984. The Company is a tissue regeneration company engaged in three segments of the wound care marketplace: pharmaceutical wound care, advanced wound care and traditional wound care products. The Company has one drug candidate that initiated its Phase 3 study. The Company maintains manufacturing facilities in Toronto, Canada and Nantong, China and an established network of third party suppliers for its products. Its products are sold through distributors to health care providers such as wound care centers, extended care facilities, acute care facilities, home health care agencies and physicians' offices. Some of its products are sold through retail channels to care givers. The Company markets its products through direct sales representatives in the United States, Canada and the United Kingdom, and through independent distributors within other select international markets. In Pharmaceutical Wound Care, the DSC127 product is in clinical trial for the treatment of diabetic foot ulcers. The Phase 3 clinical trial for diabetic foot ulcers is expected to be completed by the end of 2015. In addition to the diabetic foot ulcer indication, the Company has begun preclinical testing for scar reduction. The product lines in Advanced Wound Care include MEDIHONEY, TCC-EZ, AMNIOEXCEL and AMNIOMATRIX, XTRASORB, BIOGUARD, and ALGICELL AG. The Traditional Wound Care line consists of gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other compression devices. It also manufactures and market adhesive bandages and related first aid products for the medical, industrial, private label and retail markets. It markets a line of wound closure strips, nasal tube fasteners and a variety of catheter fasteners to doctors, clinics, nursing homes, hospitals and other institutions. In addition, the Company owns or licenses over 50 U.S. patents, corresponding foreign patents and patent applications. The patents relating to the DSC127, MEDIHONEY, BIOGUARD, AMNIOEXCEL and AMNIOMATRIX technologies are held under license agreements of indefinite duration. It is subject to the regulation regarding occupational safety, laboratory practices, environmental protection and hazardous substance control and may be subject to other present and future U.S. and foreign regulations.
» More Articles for DSCI

Headlines

Articles On GuruFocus.com
Derma Sciences Inc. Reports Operating Results (10-Q) Nov 12 2010 
Derma Sciences Inc. Reports Operating Results (10-Q) May 12 2010 

More From Other Websites
Derma Sciences Announces Publication in Advances in Wound Care Jun 25 2015
Derma Sciences Announces Publication in Advances in Wound Care Jun 25 2015
Derma Sciences Completes Non-Clinical Aclerastide Toxicology Program Jun 18 2015
Derma Sciences Completes Non-Clinical Aclerastide Toxicology Program Jun 18 2015
Derma Sciences Announces Medicare Coverage Reinstated For MEDIHONEY® Products with Reimbursable... Jun 17 2015
Derma Sciences Announces Medicare Coverage Reinstated For MEDIHONEY® Products with Reimbursable... Jun 17 2015
Sell These 7 Health Care Supplies Companies Now Jun 04 2015
DERMA SCIENCES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 29 2015
Derma Sciences Provides Update on Aclerastide Phase 3 Trials May 19 2015
Derma Sciences Provides Update on Aclerastide Phase 3 Trials May 19 2015
DERMA SCIENCES, INC. Financials May 15 2015
Derma Sciences Inc Earnings Call scheduled for 11:00 am ET today May 11 2015
Derma Sciences Reports First Quarter 2015 Financial Results May 11 2015
Derma Sciences reports 1Q loss May 11 2015
Derma Sciences reports 1Q loss May 11 2015
Q1 2015 Derma Sciences Inc Earnings Release - Before Market Open May 11 2015
Derma Sciences Reports First Quarter 2015 Financial Results May 11 2015
DERMA SCIENCES, INC. Files SEC form 10-Q, Quarterly Report May 08 2015
Derma Sciences to Hold First Quarter Financial Results Conference Call on May 11Th May 05 2015
Derma Sciences to Hold First Quarter Financial Results Conference Call on May 11Th May 05 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK